Description
Indication & Scope
BaShi® Ganciclovir for Injection provides intravenous antiviral therapy for cytomegalovirus retinitis in AIDS patients; also for severe systemic herpes‑group virus infection.
- Mechanism: Transforms to ganciclovir triphosphate inside infected host cells, inhibiting cytomegalovirus and herpes virus DNA polymerase.
- Drug class: Systemic nucleoside antiviral injectable preparation.
- Clinical use: Parenteral treatment for cytomegalovirus retinitis among AIDS patients and severe disseminated herpes‑group virus infection.
| Generic Name | Ganciclovir for Injection |
| Brand Name | BaShi® |
| Ingredient | Ganciclovir |
| Dosage Form | Injection |
| Package | 0.25g*10 vials/box;
0.125g (quantity to be determined); 0.5g (quantity to be determined) |
| Conditions Treated | CMV retinitis in AIDS patients, severe systemic herpes‑group virus infection |
| Taboos | Severe neutropenia or thrombocytopenia, confirmed hypersensitivity to ganciclovir; pregnancy and lactation are contraindications |
| Place of origin | China |
| Prescription type | Prescription‑only |
| Storage Conditions | Store at controlled room temperature, protect from light |
| Manufacturer | Hainan Beite Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20067791; H20067223; H20217111 |
| Approval Date | Dec 29, 2025; Oct 17, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Weight‑adjusted intravenous infusion dose, divided into induction phase and maintenance phase, decided by clinicians.
Time: Infusion is completed under hospital medical supervision according to treatment protocol schedule.
Instructions for use: Reconstitute and dilute before slow intravenous infusion; do not administer via rapid bolus injection. Strict hematological monitoring is required.
Interaction: Combination with imipenem‑cilastatin elevates seizure risk; concurrent myelosuppressive agents aggravate blood‑cell suppression.
Side effects:
1. Myelosuppression serves as major adverse reaction: neutropenia, thrombocytopenia.
2. Fever, gastrointestinal discomfort, hepatic function abnormality can occur.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What main infectious indication applies for Ganciclovir for Injection this injectable ganciclovir preparation?
It treats cytomegalovirus retinitis in AIDS patients and severe systemic herpes‑group virus infection.
What is the most significant adverse‑reaction risk of Ganciclovir for Injection?
Myelosuppression represented by neutropenia and thrombocytopenia counts as the primary risk.
What administration mode of Ganciclovir for Injection must be avoided during infusion operation?
Rapid bolus injection is forbidden; only slow intravenous infusion after proper dilution is permitted.
Which laboratory indicator needs close tracking in whole treatment period of Ganciclovir for Injection?
Peripheral blood cell counts should be monitored continuously for detecting bone marrow suppression.
BaShi® | Ganciclovir for Injection | Cytomegalovirus Retinitis/Severe Herpes Virus | DengYueRX
INN: Ganciclovir for Injection
Indications: Cytomegalovirus retinitis and severe herpes virus
Dosage Form: Injection
Strength: 0.25g/vial
Original price was: $1.70.$1.44Current price is: $1.44.
